Application of Toxicogenomic Technology for the Improvement of Risk Assessment
![]() |
Hwang, Myung-Sil
(Division of Risk Assessment, Department of Risk Assessment Research, National Institute of Toxicological Research)
Yoon, Eun-Kyung (Division of Risk Assessment, Department of Risk Assessment Research, National Institute of Toxicological Research) Kim, Ja-Young (Division of Risk Assessment, Department of Risk Assessment Research, National Institute of Toxicological Research) Son, Bo-Kyung (Division of Risk Assessment, Department of Risk Assessment Research, National Institute of Toxicological Research) Jang, Dong-Deuk (Division of Risk Assessment, Department of Risk Assessment Research, National Institute of Toxicological Research) Yoo, Tae-Moo (Division of Risk Assessment, Department of Risk Assessment Research, National Institute of Toxicological Research) |
1 | NRC (National Research Council). Science and judgment in risk assessment. Washington, DC; National Academy Press (1994) |
2 | Maggioli, J. et al. Toxicogenomic analysis methods for predivtive toxicology. J of Pharmaco and Toxicol Methods 53:31-37 (2006) DOI ScienceOn |
3 | Hamadeh, H. K. et al. Gene expression analysis reveals chemical-specific profiles. Toxicol Sci 67:219-231 (2002b) DOI ScienceOn |
4 | Fielden, M. R. et al. A gene expression signature that predicts the future onset of drug-induced renal tubular toxicity. Toxicol Pathol 33:675-683 (2005) DOI |
5 | Uetrecht, J. Prediction of a new drug's potential to cause idiosyncratic reactions. Curr. Opin. Drug Discov Devel 4:55-59 (2001) |
6 | Masubuchi, Y., Nakayama, S. & Horie, T. Role of mitochondrial permeability transition in diclofenacinduced hepatocyte injury in rats. Hepatology 35:544-551 (2002) DOI ScienceOn |
7 | EPA. Arsenic, inorganic. CASRN 7440-38-2. Integrated Risk Information System (IRIS). Available: http://www.epa.gov/iris/subst/0278.htm(1998b) |
8 | Ulrich, R. G. et al. Metabolic, idiosyncratic toxicity of drugs: overview of the hepatic toxicity induced by the anxiolytic, panadiplon. Chem Biol Interact 134: 251-270 (2001) DOI ScienceOn |
9 | Salerno, R. A. & Lesko, L. J. Pharmacogenomic data: FDA voluntary and required submission guidance. Pharmacogenomics 5:503-505 (2004) DOI ScienceOn |
10 | Iannaccone, P. M. Toxicogenomics: "the call of the wild chip". Environ Health Perspect 109:8-11 (2001) DOI |
11 | Aardema, M. J. & MacGregor, J. T. Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "-omics" technologies. Mutat Res 499: 13-25 (2002) DOI ScienceOn |
12 | FDA. Guidance for industry Pharmacogenomic data submissions. Washington, DC: Food and Drug Administration. Available: www.fda.gov/cder/guidance/ 6400fnl.pdf (2005) |
13 | Yang, Y., Blomme, E. A. G. & Waring, J. F. Toxicogenomics in drug discovery: from preclinical studies to clinical trials. Chem Biol Interact 150:71-85 (2004) DOI ScienceOn |
14 | Nie, A. Y. et al. Predictive toxicogenomics approaches reveal underlying molecular mechanisms of nongenotoxic carcinogenicity. Mol Carcinog 45:914-933 (2006) DOI ScienceOn |
15 | Ulrich, R. & Friend, S. H. Toxicogenomics and drug discovery: will new technologies help us produce better drugs? Nat Rev Drug Discov 1:84-88 (2002) DOI |
16 | Boelsterli, U. A. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol 192:307-322 (2003) DOI ScienceOn |
17 | Kultima, K. et al. Valproic acid teratogenicity: A toxicogenomics approach. Environ Health Perspect 112: 1225-1235 (2004) DOI ScienceOn |
18 | Hansch, C. et al. The expanding role of quantitative structure-activity relationships (QSAR) in toxicology. Toxicol Lett 79:45-53 (1995) DOI ScienceOn |
19 | Jiang, Y. et al. Diagnosis of drug-induced renal tubular toxicity using global gene expression profiles. J Trans Med 5:47-54 (2007) DOI ScienceOn |
20 | Fielden, M. R. & Zacharewski, T. R. Challenges and limitations of gene expression profiling in mechanistic and predictive toxicology. Toxicol Sci 60:6-10 (2001) DOI ScienceOn |
21 | Tong, W. et al. Assessment of prediction confidence and domain extrapolation of two structure-activity relationship models for predicting estrogen receptor binding activity. Environ Health Perspect 112:1249-1254 (2004) DOI ScienceOn |
22 | Guerreiro, N. et al. Toxicogenomics in drug development. Toxicol Pathol 31:471-479 (2003) DOI |
23 | International Agency for Research on Cancer, IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. Overall evaluations of carcinogenicity: An updating of IARC monographs Vol. 1-42, Supplement 7. Lyon, France: IARC Press. (1987) |
24 | Smith, L. L. Key challenges for toxicologists in the 21st century. Trends Pharmacol Sci 22:281-285 (2001) DOI ScienceOn |
![]() |